Status:
COMPLETED
A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the safety and effectivenes...
Eligibility Criteria
Inclusion
- Documented clinical history of genotype-1 chronic Hepatitis C and compensated liver disease
- Treatment Naive (patient has received no previous treatment for chronic hepatitis C infection)
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Patient is pregnant or breastfeeding
- Patient is co-infected with HIV or Hepatitis B
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT00118768
Start Date
August 1 2005
Last Update
March 2 2009
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States
2
San Diego, California, United States
3
San Mateo, California, United States
4
Lakewood, Colorado, United States